GO:0150079 negative regulation of neuroinflammatory response: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0150079 describes any process that stops, prevents, or reduces the frequency, rate, or extent of the neuroinflammatory response.
• Neuroinflammation is driven largely by microglia and astrocytes, and its negative regulation is essential for limiting bystander neuronal damage after infection, ischemia, or proteinopathy.
• Key molecular brakes include epigenetic regulators such as METTL3-dependent m6A modification of BATF mRNA, H3K27me3-mediated repression of Rnf19a, and PRMT2IP signaling in microglia.
• Loss of negative regulation is linked to Alzheimer's disease, post-stroke depression, Japanese encephalitis virus neuropathology, and TLR-driven autoimmunity.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate brakes on neuroinflammation.
• Combining TSPO PET imaging, transcriptomics, and functional assays provides a translational readout of neuroinflammatory tone.
Description
Neuroinflammation is a coordinated central nervous system response to infection, injury, or protein aggregation, and it is executed primarily by resident microglia and astrocytes together with peripheral immune signals. While acute neuroinflammation can be protective, unresolved or excessive activation damages neurons and contributes to chronic neurological disease. The Gene Ontology term GO:0150079, negative regulation of neuroinflammatory response, captures the endogenous processes that stop, prevent, or reduce the frequency, rate, or extent of this response. Understanding these brakes is a central goal in neuroimmunology because therapeutic strategies often aim to reinforce them rather than to abolish inflammation entirely. Mechanistically, negative regulation of neuroinflammatory response operates at multiple levels: epigenetic control of microglial gene expression, post-transcriptional stabilization or degradation of inflammatory transcripts, and receptor-proximal signaling that dampens TLR and cytokine cascades. For example, the m6A methyltransferase METTL3 stabilizes BATF mRNA in microglia and thereby drives neuroinflammation, so its negative regulation is required to restrain neurotoxicity. Similarly, H3K27me3 modification of Rnf19a promotes neuroinflammatory response during Japanese encephalitis virus infection, indicating that repressive chromatin marks can either limit or license inflammation depending on context. For researchers, GO:0150079 provides a formal framework to annotate genes and pathways that suppress neuroinflammation, to interpret transcriptomic and imaging data, and to design loss-of-function and gain-of-function experiments. This article synthesizes the QuickGO definition with verified PubMed literature to outline the mechanisms, key genes, disease links, and CRISPR-based methods used to study negative regulation of neuroinflammatory response.
negative regulation of neuroinflammatory response At A Glance
| GO ID | GO:0150079 |
|---|---|
| GO term | negative regulation of neuroinflammatory response |
| Ontology | biological_process |
| Synonym | None listed |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of neuroinflammatory response |
| Primary cell types | Microglia, astrocytes, and infiltrating immune cells |
| Representative triggers | Infection, ischemia, protein aggregation, and peripheral immune challenge |
| Representative brakes | METTL3-dependent m6A regulation, H3K27me3 marks, PRMT2IP signaling, and TLR pathway modulators |
| Disease relevance | Alzheimer's disease, post-stroke depression, viral neuropathology, and autoimmunity |
What Is GO:0150079?
GO:0150079, negative regulation of neuroinflammatory response, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the neuroinflammatory response. In practical terms, it refers to molecular and cellular events that dampen the activation of central nervous system immune responses, including microglial and astrocytic activation, cytokine production, and blood-brain barrier disruption. This term is a biological process and does not have listed synonyms in QuickGO.
Why Is negative regulation of neuroinflammatory response Important in Cell Biology?
Negative regulation of neuroinflammatory response is important because unchecked neuroinflammation is a common final pathway of neuronal injury across infectious, ischemic, and neurodegenerative conditions. Without effective brakes, microglial activation and cytokine release can amplify blood-brain barrier dysfunction and neuronal loss. Conversely, enhancing these endogenous suppressive mechanisms is a rational therapeutic strategy for diseases such as Alzheimer's disease and post-stroke depression. Therefore, defining the genes and pathways that execute GO:0150079 is essential for target discovery and for interpreting preclinical models.
• Limits bystander neuronal damage after infection or ischemia.
• Prevents chronic microglial activation that contributes to neurodegeneration.
• Modulates blood-brain barrier integrity during peripheral infection.
• Shapes outcomes in post-stroke depression and mood disorders.
• Controls viral neuropathology such as Japanese encephalitis virus infection.
• Dampens TLR-mediated autoimmunity through regulators like UNC93B1.
• Provides mechanistic targets for epigenetic and post-transcriptional therapies.
• Enables interpretation of TSPO PET imaging and transcriptomic signatures.
• Guides CRISPR-based causal validation of candidate suppressor genes.
• Supports development of biomarkers for neuroinflammatory tone.
What Happens During negative regulation of neuroinflammatory response?
Sensing and initiation of neuroinflammation
In simple terms: First, the brain detects danger signals and starts an immune response.
Neuroinflammation is initiated when microglia and astrocytes sense pathogens, damage-associated molecules, or peripheral immune signals. In mouse models, lung infection by Pseudomonas aeruginosa induces neuroinflammation and blood-brain barrier dysfunction, showing that peripheral insults can trigger central responses. Similarly, amyloid-beta deposition is associated with neuroinflammatory signatures in Alzheimer's disease. These initiation events are the substrate that negative regulation must counteract.
Epigenetic brakes on microglial activation
In simple terms: Chemical marks on DNA and histones can turn down inflammatory genes.
Epigenetic mechanisms provide durable brakes on neuroinflammatory gene expression. H3K27me3 of Rnf19a promotes neuroinflammatory response during Japanese encephalitis virus infection, indicating that repressive histone marks can modulate the intensity of microglial activation. In addition, the m6A methyltransferase METTL3 drives neuroinflammation and neurotoxicity by stabilizing BATF mRNA in microglia, so negative regulation of this axis restrains neurotoxicity. These findings place chromatin and RNA modification at the center of GO:0150079.
Post-transcriptional and signaling suppression
In simple terms: Cells can degrade or block inflammatory messages after they are made.
Negative regulation also occurs after transcription. METTL3-dependent m6A modification stabilizes BATF mRNA, and interfering with this stabilization reduces neuroinflammation and neurotoxicity. Microglial PRMT2IP alleviates ischemia-induced brain injury, providing an example of an endogenous suppressor that limits neuroinflammatory damage. In parallel, variants in UNC93B1 can drive TLR-mediated autoimmunity, highlighting that proper control of TLR trafficking and signaling is required to prevent excessive inflammatory responses.
Resolution and tissue protection
In simple terms: Finally, the response is resolved so that neurons can survive.
Effective negative regulation leads to resolution of microglial activation and protection of neuronal tissue. PRMT2IP signaling in microglia alleviates ischemia-induced brain injury, demonstrating that endogenous suppressive pathways can improve outcomes after stroke. In Alzheimer's disease, integrating TSPO PET imaging with transcriptomics reveals that neuroinflammation and amyloid-beta deposition are linked, so therapies that enhance negative regulation may reduce pathology. Post-stroke depression is also associated with neuroinflammatory mechanisms, and pharmacological treatment strategies often target these pathways.
Microenvironmental and material cues
In simple terms: The physical environment around microglia can also change their behavior.
Beyond soluble signals, physical cues influence microglial phenotype. Textured nanofibrils drive microglial phenotype, showing that biomaterial topography can modulate activation states relevant to neuroinflammation. Such findings expand the scope of GO:0150079 by indicating that negative regulation can be influenced by the extracellular microenvironment and engineered surfaces.
Key Genes Involved in GO:0150079 negative regulation of neuroinflammatory response
The following genes and proteins have been experimentally linked to negative regulation of neuroinflammatory response or to the neuroinflammatory processes it controls.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | m6A methyltransferase that stabilizes BATF mRNA in microglia | Drives neuroinflammation and neurotoxicity; target for negative regulation |
| BATF | Transcription factor stabilized by METTL3 in microglia | Mediates neuroinflammatory gene expression |
| Rnf19a | E3 ubiquitin ligase regulated by H3K27me3 | Promotes neuroinflammatory response during Japanese encephalitis virus infection |
| PRMT2IP | Microglial signaling protein | Alleviates ischemia-induced brain injury |
| UNC93B1 | TLR trafficking chaperone | Variants drive TLR-mediated autoimmunity in mice and humans |
| TSPO | Mitochondrial translocator protein imaging target | Marker of neuroinflammation in Alzheimer's disease |
| APP | Amyloid precursor protein | Amyloid-beta deposition linked to neuroinflammation |
| IL-1beta | Pro-inflammatory cytokine | Readout of neuroinflammatory response |
| TNF-alpha | Pro-inflammatory cytokine | Readout of neuroinflammatory response |
| GFAP | Astrocyte activation marker | Indicator of neuroinflammatory response |
| IBA1 | Microglial activation marker | Indicator of microglial response |
| TLR4 | Pattern recognition receptor | Initiates inflammatory signaling modulated by UNC93B1 |
| TLR7 | Endosomal nucleic acid sensor | Associated with UNC93B1-dependent autoimmunity |
| NF-kB | Transcription factor | Central mediator of neuroinflammatory gene expression |
| STAT1 | Transcription factor | Downstream of cytokine signaling in neuroinflammation |
| CXCL10 | Chemokine | Recruits immune cells during neuroinflammation |
| CCL2 | Chemokine | Monocyte recruitment in neuroinflammation |
| BDNF | Neurotrophic factor | Linked to post-stroke depression mechanisms |
How Is negative regulation of neuroinflammatory response Regulated?
Negative regulation of neuroinflammatory response is itself controlled at multiple levels. Epigenetic regulation includes H3K27me3 marks that influence Rnf19a expression during viral infection and m6A RNA modification that controls BATF mRNA stability. Signaling regulation includes PRMT2IP, which alleviates ischemia-induced brain injury, and UNC93B1-dependent control of TLR trafficking, where variants can drive autoimmunity. Microenvironmental cues such as textured nanofibrils can also shift microglial phenotype. Together, these layers determine the set point of neuroinflammatory tone.
negative regulation of neuroinflammatory response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Neuroinflammation and neurotoxicity | Microglial knockout and overexpression models |
| Rnf19a | Japanese encephalitis virus neuropathology | H3K27me3 perturbation and viral infection models |
| PRMT2IP | Ischemic brain injury | Knockout and knock-in mouse models of stroke |
| UNC93B1 | TLR-mediated autoimmunity | Point-mutation knock-in models in mice |
| TSPO | Alzheimer's disease neuroinflammation | PET imaging and transcriptomics in disease models |
Alzheimer's disease and proteinopathy
Alzheimer's disease is characterized by amyloid-beta deposition and accompanying neuroinflammation. Integrating TSPO PET imaging with transcriptomics has been used to unveil the role of neuroinflammation and amyloid-beta deposition in Alzheimer's disease, supporting the idea that failed negative regulation contributes to pathology. Enhancing endogenous brakes on neuroinflammation is therefore a candidate therapeutic strategy.
Post-stroke depression and ischemia
Post-stroke depression is linked to neuroinflammatory mechanisms, and pharmacological treatments often target these pathways. Microglial PRMT2IP alleviates ischemia-induced brain injury, indicating that endogenous negative regulation can protect against ischemic damage. These findings connect GO:0150079 to both acute injury and chronic mood outcomes.
Viral neuropathology
Japanese encephalitis virus infection is associated with H3K27me3-mediated regulation of Rnf19a that promotes neuroinflammatory response. This illustrates how viral pathogens can co-opt or override negative regulatory mechanisms, leading to excessive neuroinflammation. Understanding these interactions may inform host-directed therapies.
TLR-driven autoimmunity and infection
UNC93B1 variants drive TLR-mediated autoimmunity in mice and humans, showing that dysregulated TLR trafficking can break tolerance. In parallel, lung infection by Pseudomonas aeruginosa induces neuroinflammation and blood-brain barrier dysfunction in mice, demonstrating that peripheral infections can trigger central inflammatory responses. Both contexts highlight the importance of negative regulation in preventing collateral damage.
From negative regulation of neuroinflammatory response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene a brake on neuroinflammation? | CRISPR knockout in microglial cell lines or primary microglia |
| Does a specific variant alter TLR trafficking? | Point-mutation knock-in of UNC93B1 variants |
| Does a disease-associated mutation affect neuroinflammatory tone? | Knock-in of patient-derived mutations followed by cytokine profiling |
| Where and when is a suppressor expressed? | Tagged knock-in with fluorescent or epitope tag |
| Does increasing a brake reduce neuroinflammation? | Overexpression of candidate genes such as PRMT2IP |
| Can epigenetic modifiers be targeted therapeutically? | CRISPR interference or activation screens for METTL3 and Rnf19a |
How to Study the negative regulation of neuroinflammatory response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| TSPO PET imaging | Neuroinflammatory signal in vivo | Alzheimer's disease studies |
| Transcriptomics | Gene expression signatures | Identifying negative regulators |
| m6A mapping | RNA modification sites | METTL3-BATF axis studies |
| ChIP for H3K27me3 | Repressive chromatin marks | Rnf19a regulation in viral infection |
| Cytokine profiling | IL-1beta, TNF-alpha, CXCL10, CCL2 levels | Microglial activation assays |
| Blood-brain barrier permeability assays | Barrier integrity | Infection-induced neuroinflammation |
| Microglial morphology imaging | Activation state | Nanofibril-driven phenotype studies |
| CRISPR screens | Candidate suppressor genes | Discovery of negative regulators |
Transcriptomic and imaging readouts
Integrating TSPO PET imaging with transcriptomics allows researchers to link neuroinflammatory signals to molecular profiles in Alzheimer's disease models. Such multimodal approaches can reveal whether candidate negative regulators shift the balance between amyloid-beta deposition and inflammation.
Epigenetic and RNA modification assays
Because H3K27me3 of Rnf19a and METTL3-dependent m6A modification of BATF mRNA regulate neuroinflammation, chromatin immunoprecipitation and m6A mapping are useful methods. These assays can identify the epigenetic and epitranscriptomic marks that enforce negative regulation.
Microglial phenotype and functional assays
Textured nanofibrils drive microglial phenotype, so in vitro systems that control surface topography can be used to study how microenvironmental cues affect negative regulation. Cytokine secretion, phagocytosis, and morphological profiling are common readouts.
Infection and injury models
Lung infection by Pseudomonas aeruginosa induces neuroinflammation and blood-brain barrier dysfunction in mice, providing a model to test negative regulators of neuroinflammation. Ischemia models and Japanese encephalitis virus infection models similarly allow assessment of endogenous brakes.
How CRISPR Can Be Used to Study GO:0150079 negative regulation of neuroinflammatory response
Knockout
CRISPR knockout of candidate genes such as METTL3 or PRMT2IP can test whether they are required for negative regulation of neuroinflammatory response. Loss-of-function models often show increased cytokine release or worsened injury, supporting a causal role.
Point Mutation
Point-mutation models are valuable for studying variants such as UNC93B1 that drive TLR-mediated autoimmunity. Introducing precise mutations allows researchers to separate trafficking defects from signaling defects in neuroinflammatory regulation.
Knock-in
Knock-in of tagged or patient-derived alleles enables tracking of protein localization and function in microglia. For example, tagging Rnf19a or METTL3 can reveal how epigenetic and RNA-modifying enzymes are recruited during neuroinflammation.
Overexpression
Overexpression of putative brakes such as PRMT2IP can test whether increasing their levels alleviates neuroinflammatory injury. Such gain-of-function experiments complement knockout studies and support therapeutic target validation.
How EDITGENE Supports negative regulation of neuroinflammatory response Research
Researchers studying negative regulation of neuroinflammatory response-related genes often need to determine whether a candidate gene is causally involved in dampening microglial activation or whether it is merely a correlative marker. CRISPR-based models provide the necessary causal evidence by allowing precise knockout, point mutation, knock-in, and overexpression of genes such as METTL3, Rnf19a, PRMT2IP, and UNC93B1.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of neuroinflammatory response research.
Frequently Asked Questions About negative regulation of neuroinflammatory response
What is GO:0150079 negative regulation of neuroinflammatory response?
GO:0150079 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the neuroinflammatory response.
What genes are involved in negative regulation of neuroinflammatory response?
Genes experimentally linked to this process include METTL3, BATF, Rnf19a, PRMT2IP, and UNC93B1, among others.
How does METTL3 regulate neuroinflammation?
METTL3 drives neuroinflammation and neurotoxicity by stabilizing BATF mRNA in microglia through m6A modification.
What is the role of Rnf19a in neuroinflammation?
H3K27me3 of Rnf19a promotes neuroinflammatory response during Japanese encephalitis virus infection.
How is neuroinflammation linked to Alzheimer's disease?
Integrating TSPO PET imaging and transcriptomics has unveiled the role of neuroinflammation and amyloid-beta deposition in Alzheimer's disease.
What is the connection between neuroinflammation and post-stroke depression?
Post-stroke depression is associated with neuroinflammatory mechanisms, and pharmacological treatments often target these pathways.
Can CRISPR be used to study negative regulation of neuroinflammatory response?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate genes in microglial and neuronal systems.
What models are used to study neuroinflammation?
Models include lung infection by Pseudomonas aeruginosa, ischemia models, Japanese encephalitis virus infection, and textured nanofibril systems for microglial phenotype.
What imaging methods measure neuroinflammation?
TSPO PET imaging is used to measure neuroinflammatory signals in vivo and can be integrated with transcriptomics.
Why is negative regulation of neuroinflammation important therapeutically?
Enhancing endogenous brakes may limit neuronal damage in Alzheimer's disease, stroke, viral neuropathology, and autoimmune conditions.
Conclusion
GO:0150079, negative regulation of neuroinflammatory response, defines the endogenous processes that restrain microglial and astrocytic activation. Experimental evidence implicates epigenetic, epitranscriptomic, and signaling mechanisms involving METTL3, BATF, Rnf19a, PRMT2IP, and UNC93B1 in this regulation. Dysregulation of these brakes is associated with Alzheimer's disease, post-stroke depression, viral neuropathology, and autoimmunity. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the causal evidence needed to translate these findings into therapeutic strategies.
References
- 1. Villa RF et al.. 2018. Post-stroke depression: Mechanisms and pharmacological treatment.. Pharmacol Ther 184:131-144 PMID: 29128343
- 2. Villalba N et al.. 2023. Lung infection by Pseudomonas aeruginosa induces neuroinflammation and blood-brain barrier dysfunction in mice.. J Neuroinflammation 20(1):127 PMID: 37245027
- 3. Rael VE et al.. 2024. Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans.. J Exp Med 221(8) PMID: 38780621
- 4. Wu X et al.. 2025. The m(6)A methyltransferase METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia.. Cell Death Differ 32(1):100-117 PMID: 38902548
- 5. Zhang M et al.. 2024. Integrating TSPO PET imaging and transcriptomics to unveil the role of neuroinflammation and amyloid-β deposition in Alzheimer's disease.. Eur J Nucl Med Mol Imaging 51(2):455-467 PMID: 37801139
- 6. Zhu S et al.. 2023. H3K27me3 of Rnf19a promotes neuroinflammatory response during Japanese encephalitis virus infection.. J Neuroinflammation 20(1):168 PMID: 37480121
- 7. Zhang M et al.. 2026. Microglial PRMT2IP alleviates ischemia-induced brain injury.. Brain Behav Immun 136:106558 PMID: 41887540
- 8. Song Q et al.. 2020. Textured nanofibrils drive microglial phenotype.. Biomaterials 257:120177 PMID: 32682149
